×
About 10,662 results
Psoriatic Arthritis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK547710/

Sep 19th, 2019 - Psoriatic arthritis (PsA) is chronic inflammatory arthritis associated with psoriasis (PsO) and found in about 20 to 30% of such patients.[1] It shares many clinical features with other spondyloarthropathies and also rheumatoid arthritis (RA). It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodi...

Lupus Erythematosus - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK535405/

Apr 19th, 2019 - The acute form of systemic lupus erythematosus (SLE) differs from the chronic form. It disseminates differently, and it is highly fatal. Kaposi was the first in recognizing SLE in 1872, and then Pernet described it in 1908. Before that time SLE was considered to be a non-fatal disfiguring skin disease. It is now to be considered a chronic inflammatory disease characterized by a course of altern...

Distinguishing rheumatoid arthritis from psoriatic arthritis
https://rmdopen.bmj.com/content/4/2/e000656
RMD Open; Merola, J. et. al.

Aug 12th, 2018 - Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have key differences in clinical presentation, radiographic findings, comorbidities and pathogenesis to distinguish between these common forms of chronic inflammatory arthritis. Joint involvement is typically, but not always, asymmetric in PsA, while it is predominantly symmetric in RA. Bone erosions, without new bone growth, and cervical ...

Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560667
Annals of the Rheumatic Diseases; Lu N, Dubreuil M et. al.

Mar 5th, 2015 - While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, the antioxidant effects of uric acid may have neuroprotective benefits. We evaluated the potential impact of incident gout on the risk of developing Alzheimer's disease (AD) in a general population context. We conducted an age-matched, sex-matched, entry-time-matched and body mass index (BMI)-matched c...

Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: ...
https://doi.org/10.7326/M18-1167
Annals of Internal Medicine; Solomon DH, Glynn RJ et. al.

Sep 22nd, 2018 - Although studies have shown that interleukin-1β (IL-1β) inhibitors can shorten gout attacks, whether they can prevent gout attacks is unclear. To examine the relationship among canakinumab, a monoclonal antibody targeting IL-1β; serum uric acid levels; and the incidence of gout attacks. Secondary exploratory analysis of a randomized controlled trial. (ClinicalTrials.gov: NCT01327846). Many clin...

Cancer risk associated with chronic diseases and disease markers: prospective cohort st...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791146
BMJ (Clinical Research Ed.); Tu H, Wen CP et. al.

Feb 1st, 2018 - To assess the independent and joint associations of major chronic diseases and disease markers with cancer risk and to explore the benefit of physical activity in reducing the cancer risk associated with chronic diseases and disease markers. Prospective cohort study. Standard medical screening program in Taiwan. 405 878 participants, for whom cardiovascular disease markers (blood pressure, tota...

Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667873
PloS One; Su X, Xu B et. al.

Nov 2nd, 2017 - The effects of uric acid-lowering therapy in patients with chronic kidney disease (CKD) remain uncertain. Therefore, we undertook a systematic review and meta-analysis to investigate the effects of uric acid-lowering agents on major clinical outcomes of CKD. According to the pre-specified protocol that was registered with PROSPERO (No. CRD42016038030), we searched systematically in MEDLINE, EMB...

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461476
BMJ (Clinical Research Ed.); Li X, Meng X et. al.

Jun 8th, 2017 - Objective To map the diverse health outcomes associated with serum uric acid (SUA) levels.Design Umbrella review.Data sources Medline, Embase, Cochrane Database of Systematic Reviews, and screening of citations and references.Eligibility criteria Systematic reviews and meta-analyses of observational studies that examined associations between SUA level and health outcomes, meta-analyses of rando...

Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease.
https://doi.org/10.1210/jc.2016-3189
The Journal of Clinical Endocrinology and Metabolism; Shah S, Chiang C et. al.

Apr 5th, 2017 - Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so ...

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controll...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530336
Annals of the Rheumatic Diseases; Bardin T, Keenan RT et. al.

Nov 8th, 2016 - Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level of ≥6.5 mg/dL (≥387 µmol/L) at screening and two or more gout flares in the prior year. Primary end point was the propo...

Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-As...
https://doi.org/10.1016/j.cgh.2016.09.158
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association; Bonacci M, Lens S et. al.

Oct 11th, 2016 - Cryoglobulins (circulating immune complexes of polyclonal IgG, monoclonal IgM, and rheumatoid factor) are detected in the circulation of 40% to 60% of patients with chronic hepatitis C virus infection, and cryoglobulinemic vasculitis (CV) is observed in approximately 10% of patients. We aimed to assess the clinical and immune effects of direct-acting antiviral treatment. We performed a prospect...

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Stu...
https://doi.org/10.1002/art.39840
Arthritis & Rheumatology (Hoboken, N.J.); Saag KG, Fitz-Patrick D et. al.

Aug 26th, 2016 - Lesinurad is a selective uric acid reabsorption inhibitor used for the treatment of gout in combination with a xanthine oxidase inhibitor. The Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR 1) study, a 12-month, multicenter, randomized, double-blind, placebo-controlled phase III trial, was conducted to investigate daily lesinurad (200 mg or 400 mg orally) ...

Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomi...
https://doi.org/10.1016/S1474-4422(14)70054-7
The Lancet. Neurology; Chamorro A, Amaro S et. al.

Apr 7th, 2014 - Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. We assessed whether uric acid therapy would improve functional outcomes at 90 days in patients with acute ischaemic stroke. URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients ...

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725733
Arthritis & Rheumatology (Hoboken, N.J.); Dalbeth N, Saag KG et. al.

Oct 4th, 2017 - To assess the effect of treatment with febuxostat versus placebo on joint damage in hyperuricemic subjects with early gout (1 or 2 gout flares). In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7.0 mg/dl) and early gout were randomized 1:1 to receive once-daily febuxostat 40 mg (increased to 80 mg if the serum UA level was ≥6.0 mg/d...

High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581496
Arthritis Research & Therapy; Takeuchi T, Miyasaka N et. al.

Sep 3rd, 2017 - Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and...

Demographic and clinical characteristics of patients with serum sickness-like reaction.
https://doi.org/10.1007/s10067-017-3777-4
Clinical Rheumatology; Yorulmaz A, Akın F et. al.

Aug 10th, 2017 - In this study, we aimed to review the demographic, clinical, and laboratory characteristics of patients who were followed up and treated with the diagnosis of serum sickness-like reactions (SSLR) in our pediatric rheumatology clinic retrospectively and emphasize the importance of early diagnosis and treatment. The files of 29 patients who were hospitalized in the pediatric rheumatology clinic b...

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601200
Arthritis & Rheumatology (Hoboken, N.J.); Dalbeth N, Jones G et. al.

Jun 9th, 2017 - To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. Patients with serum urate (UA) ≥8.0 mg/dl (≥6.0 mg/dl with urate-lowering therapy) and ≥1 measurable target tophus were given febuxostat 80 mg/day for 3 weeks before randomization to receive lesinurad (200 or 400 mg daily) or placebo in addition to t...

Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a ret...
https://doi.org/10.1007/s12630-017-0865-5
Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie; Kraeva N, Sapa A et. al.

Mar 22nd, 2017 - Two potentially fatal syndromes, malignant hyperthermia (MH), an adverse reaction to general anesthesia, and exertional rhabdomyolysis (ER) share some clinical features, including hyperthermia, muscle rigidity, tachycardia, and elevated serum creatine kinase. Some patients with ER have experienced an MH event and/or have been diagnosed as MH susceptible (MHS). In order to assess the relationshi...

Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Y...
https://doi.org/10.1002/acr.23217
Arthritis Care & Research; Carpenter L, Norton S et. al.

Feb 21st, 2017 - To assess the 5-year progression of erosions and joint space narrowing (JSN) and their associations with rheumatoid factor (RF) status in 2 large, multicenter, early rheumatoid arthritis cohorts, spanning 25 years. Radiographic joint damage was recorded using the Sharp/van der Heijde (SHS) method in the Early Rheumatoid Arthritis Study (ERAS), 1986-2001, and the Early Rheumatoid Arthritis Netwo...

Serial echocardiography for immune-mediated heart disease in the fetus: results of a ri...
https://doi.org/10.1002/pd.5021
Prenatal Diagnosis; Kan N, Silverman ED et. al.

Feb 8th, 2017 - Mothers carrying anti-Ro antibodies are frequently referred for weekly echocardiograms to early detect and treat antibody-mediated fetal heart disease. We tested a surveillance strategy based on anti-Ro antibody titers. From 2009 to 2014, 232 pregnancies were referred for maternal anti-Ro antibodies. At the baseline echocardiogram, anti-Ro titers were measured by enzyme-linked immunosorbent ess...